Henry Schein stock rose 5.8% following several positive developments. The company beat fourth-quarter profit estimates and provided annual profit guidance largely in line with Wall Street expectations, driven by stabilizing demand for dental and medical equipment. Baird upgraded Henry Schein from Neutral to Outperform with a price target of $100.00, citing modest improvements in North American dental patient volumes and increased consumables pricing. Baird anticipates stable to improved year-over-year growth for the company's U.S. dental consumables revenue, potentially reaching 5% or higher in the fourth quarter of 2025. The upgrade was supported by Henry Schein's attractive valuation metrics and recent executive appointments.
Read full analysisHenry Schein stock rose 5.8% following several positive developments. The company beat fourth-quarter profit estimates and provided annual profit guidance largely in line with Wall Street expectations, driven by stabilizing demand for dental and medical equipment. Baird upgraded Henry Schein from Neutral to Outperform with a price target of $100.00, citing modest improvements in North American dental patient volumes and increased consumables pricing. Baird anticipates stable to improved year-over-year growth for the company's U.S. dental consumables revenue, potentially reaching 5% or higher in the fourth quarter of 2025. The upgrade was supported by Henry Schein's attractive valuation metrics and recent executive appointments.
Henry Schein is a major distributor of healthcare products and services to dental and medical practitioners, also offering practice management software through its Henry Schein One subsidiary. The stock had been under pressure since mid-January following the CEO transition from longtime leader Stanley Bergman to Frederick Lowery. Today's Q4 earnings beat, combined with Baird's upgrade citing dental market recovery and a $100 price target, effectively de-risked the leadership change and triggered the stock's highest-volume session in recent memory.